What is Roth Capital’s Forecast for Accuray FY2026 Earnings?

Accuray Incorporated (NASDAQ:ARAY) – Equities research analysts at Roth Capital upped their FY2026 EPS estimates for shares of Accuray in a research report issued on Tuesday, November 19th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings of $0.11 per share for the year, up from their prior estimate of $0.08. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter last year, the business posted ($0.03) earnings per share.

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Performance

NASDAQ ARAY opened at $1.93 on Friday. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray has a 1-year low of $1.40 and a 1-year high of $3.05. The business has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $1.83. The stock has a market capitalization of $194.10 million, a PE ratio of -11.35 and a beta of 1.40.

Institutional Investors Weigh In On Accuray

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its stake in shares of Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 15,209 shares during the period. AQR Capital Management LLC bought a new position in Accuray during the 2nd quarter valued at about $30,000. US Bancorp DE raised its position in Accuray by 1,087.7% in the 3rd quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 16,316 shares during the period. Caprock Group LLC bought a new stake in Accuray in the third quarter worth about $36,000. Finally, Intech Investment Management LLC purchased a new position in shares of Accuray during the third quarter valued at approximately $41,000. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.